All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2019-02-26T17:36:40.000Z

ISAL 2019 | Stratification of genetic risk factors in acute myeloid leukemia

Feb 26, 2019
Share:

Bookmark this article

On 25 February 2019 at the Acute Leukemias XVII Biology and Treatment Strategies biennial symposium in Munich, Germany, Klaus Metzeler from the Ludwig Maximilian University of Munich, Munich, Germany, presented data from a study which aimed to validate the European LeukemiaNet (ELN) genetic risk stratification system in adult patients with acute myeloid leukemia (AML), who received cytarabine and anthracycline induction chemotherapy enrolled on acute myeloid leukemia cooperative group (AMLCG) trials.1,2

Overall, patients included in this study (n = 1118; median age = 58 years; range, 18–86) were analyzed in two cohorts. The incidence cohort (n = 772) included patients with all cytogenetic categories from the AMLCG-1999 and AMLCG-2008 studies, in genetically unselected patients. The extension cohort (n = 346) included patients with AML who had normal cytogenetic characteristics from the AMLCG-1999 study, with patients only included in the outcome analyses. Patients underwent genetic analysis, including sequencing for mutations in the NPM1, FLT3, CEBPA, RUNX1, ASXL1, and TP53 genes.

Key findings

Data shown based on the ELN 2017 classification

  • Compared with the ELN 2010 classification, 27% of patients (n = 772) were reassigned to a category associated with an adverse risk or a more favorable outcome
  • In patients ≥ 60 years, only 27.7% (n = 95) were classified with favorable genetic risk status compared to 41.3% (n = 177) in patients aged < 60 years
  • Complete remission (CR) rates in the total population (n = 1118, P < 0.0001) vs patients < 60 years vs patients ≥ 60 years, who received induction chemotherapy:
    • Favorable genetic risk (n = 428): 72% vs 75% vs 68%
    • Intermediate genetic risk (n = 290): 67% vs 66% vs 66%
    • Adverse genetic risk (n = 400): 40% vs 43% vs 39%
  • Five-year relapse-free survival (RFS) in all age groups, P < 0.0001:
    • Favorable genetic risk (n = 306): 54%
    • Intermediate genetic risk (n = 193): 26%
    • Adverse genetic risk (n = 161): 12%
  • Five-year overall survival (OS) in patients < 60 years (n = 601) vs ≥ 60 years (n = 517) , P < 0.0001:
    • Favorable genetic risk: 64% (n = 265) vs 36% (n = 163)
    • Intermediate genetic risk: 41% (n = 167) vs 15% (n = 123)
    • Adverse genetic risk: 19% (n = 169) vs 6% (n = 231)
  • In patients aged ≥ 75 years who have received intensive therapy, the ELN 2017 risk classification is uncertain, with prognostic indicators having less relevance in this population
  • Outcomes are similar between favorable risk patients in the ELN 2017 and ELN 2010 groups, however, ELN 2017 improves risk stratification through the identification of greater numbers of high risk and low risk patients with AML

Data shown from the refined ELN 2017 classification using established prognostic markers

  • Five-year OS in patients possessing mutated biCEBPA, inv(16), or t(16;16), defined as very favorable genetic risk: 69%
  • Five-year OS in patients harboring mutated TP53 and complex karyotype, defined as very adverse genetic risk: 0%

Data shown from the refined ELN 2017 classification using the incorporation of additional pretreatment markers

  • Shorter OS and event-free survival (EFS) was shown to associate with a high mutant NPM1 allele burden
  • Multivariate analysis illustrated factors associating with OS:
    • FLT3-ITDhigh:WT ratio: HR = 2.2 (95% CI, 1.6–2.9), P < 0.0001
    • Mutant DNMT3A: HR = 1.4 (95% CI, 1.1–1.9), P = 0.008

In conclusion, the ELN 2017 classification allows validated genetic risk based stratification of patients with AML receiving cytarabine and anthracycline induction chemotherapy. Furthermore, the study concluded that more patients are classified with favorable or adverse risk AML, and less as intermediate risk AML compared to the ELN 2010 classification system. Moreover, this study illustrates the possibility for further refinement of the ELN 2017 genetic risk classification system. The relevance of the risk classification system is unclear in patients receiving alternative therapies, such as venetoclax, or the effect of molecularly targeted agents, as it has been established primarily in patients receiving induction chemotherapy. Klaus Metzeler stated the importance of integrating pre-treatment risk classification with the measures of response and residual disease post-treatment. This study highlights that the future challenge is the integration of a multidimensional model to effectively aid in the selection of the most promising sequence of therapies for patients with AML.

  1. Döhner H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26; 129(4): 424–447. DOI: https://doi.org/10.1182/blood-2016-08-733196.
  2. Metzeler K. et al. Pretreatment Risk Stratification of AML - ELN and Beyond. 2019 Feb 25: ACUTE LEUKEMIAS XVII Biology and Treatment Strategies, Munich, Germany.

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
14 votes - 2 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox